Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Long-Term Outcomes of Orbital Fat Decompression in Graves’ Orbitopathy
source: The British Journal of Ophthalmology
year: 2018
authors: Cheng AM, Wei YH, Tighe S, Sheha H, Liao SL
summary/abstract:Purpose:
To evaluate the long-term clinical efficacy of orbital fat decompression in treating proptosis in Graves’ ophthalmopathy (GO).
Methods:
Retrospective review of 1604 eyes of 845 patients with symmetric (1518 eyes) and asymmetric (86 eyes) proptosis who received orbital fat decompression between 2003 and 2014. Changes in Hertel values were evaluated at baseline, 6 months postoperatively and yearly thereafter. Recurrence of proptosis, diplopia and other complications that required additional surgeries were documented and analysed. The surgical outcome was defined as complete success if there was proptosis reduction with no recurrence and improved or no diplopia. Partial success was considered if there was proptosis reduction without recurrence yet persistent or new-onset diplopia. Failure was considered if there was recurrence of proptosis regardless of diplopia. The patient’s quality of life was also evaluated as a long-term outcome.
Results:
After follow-up for 37.9±24.4 months, 1365 eyes (85.1%) achieved complete success, 219 eyes (13.7%) achieved partial success and 20 eyes (1.2%) had failure. Newly onset diplopia and secondary decompression occurrence rate remained low at 3.3% and 0.6%, respectively. The total proptosis reduction was 4.1±1.3 mm, which was consistent all through the intermediate and long-term (5-10 years) follow-up. The amount of orbital fat removal (4.5±1.1 mL) played a significant role in the long-term Hertel change. Importantly, the overall quality of life increased significantly for GO patients after undergoing orbital fat decompression.
Conclusions:
Orbital fat decompression has a long-term efficacy in correcting disfiguring proptosis with a low complication rate and without the need of secondary decompression procedures. This was also associated with a significant improvement in quality of life.
DOI: 10.1136/bjophthalmol-2016-309888
read more
Related Content
-
New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
-
Warning Signs of Graves’ Disease and Thyroid Eye Diseasehttps://mms.businesswire.com/media/20190...
-
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
-
Surgical Treatment of Diplopia in Graves’ Orbitopathy PatientsPurpose: To review the authors' current...
-
A New Era in the Treatment of Thyroid Eye DiseasePurpose: Improved understanding of thyr...
-
Pathogenesis of Thyroid Eye Disease: Review and Update on Molecular MechanismsOrbital changes in thyroid orbitopathy (...
-
Smoking Induces Overexpression of Immediate Early Genes in Active Graves’ OphthalmopathyBackground: Cigarette smoking is a risk...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.